Metabolic & Weight

• The two receptor-coverage tiers Veyvora stocks, dual GIP/GLP-1 and triple GIP/GLP-1/glucagon, determine which mechanistic questions each compound can address in an assay or animal model.
• Procurement decisions rest on verification across four distinct quality dimensions: identity, analytical documentation, pen specification, and cold-chain records.
• All materials and discussion on this page are for laboratory and in-vitro research; not for human or veterinary use.

Dual agonist peptides such as Tirzepatide and triple agonist compounds such as Retatrutide are the two receptor-coverage tiers Veyvora stocks in this category. Each tier is defined by the number of receptors engaged: Tirzepatide engages the GLP-1 and GIP receptors; Retatrutide engages GLP-1, GIP and glucagon receptors simultaneously, adding glucagon receptor activity that the dual agonist does not cover. For context, a single GLP-1 agonist activates the glucagon-like peptide-1 receptor only, but Veyvora does not stock a single-agonist compound. That receptor-coverage hierarchy is the primary mechanistic distinction between catalogue entries in this class, and the correct starting point for any procurement or assay-design decision.

Veyvora’s metabolic research peptide category lists compounds classified by receptor engagement profile: dual GIP/GLP-1 agonists and triple GIP/GLP-1/glucagon agonists. All materials are supplied for laboratory and in-vitro research.

Verified Catalogue Entities

Two compounds are confirmed within this category from current Veyvora source content:

• Tirzepatide, classified as a dual GIP/GLP-1 receptor agonist. The 2025 systematic review identifies tirzepatide’s receptor profile as GLP-1 and GIP co-engagement [1]. Veyvora lists Tirzepatide for laboratory research, as of 2026.
• Retatrutide, classified as a triple GIP/GLP-1/glucagon receptor agonist. The same 2025 systematic review identifies retatrutide as engaging GLP-1, GIP and glucagon receptors [1]. Veyvora lists Retatrutide for laboratory research, as of 2026. For compound-specific mechanism and research context, see the Retatrutide triple-agonist profile.
• Pen format, Veyvora states that the Retatrutide 40 mg pen is a pre-filled 3 mL, 300-click solution pen. The micrograms-per-click figure is product-specific and is read from each individual product page or certificate of analysis. Confirm the fill mass and click dose for each compound before designing a protocol for an in-vitro or animal model.

Scope Boundary

Single-agent GLP-1 receptor agonists such as Semaglutide and Liraglutide appear in comparative primary literature, but they are not part of Veyvora’s metabolic pen catalogue, which comprises the dual agonist Tirzepatide and the triple agonist Retatrutide. For a receptor-level contrast between the single-agonist and dual-agonist classes, see the tirzepatide versus semaglutide comparison.

Published evidence for GLP-1 receptor agonists, dual agonist peptides and triple agonist compounds spans three distinct tiers, each answering its own question.

Mechanistic and preclinical evidence establishes receptor engagement and downstream signalling in cell assays or animal models. The 2025 systematic review identifies retatrutide’s additional glucagon receptor engagement as the mechanistic feature that distinguishes it from tirzepatide’s dual GIP/GLP-1 profile [1]. The two compounds therefore activate different receptor combinations and produce distinct downstream signalling patterns in experimental systems. That characterisation reflects receptor-level pharmacology, and effects in other species, cell lines or experimental systems are established in those systems.

Clinical trial evidence for tirzepatide is more extensive than for retatrutide as of 2025, with tirzepatide supported by randomised controlled trial data in human populations, while retatrutide’s published depth is weighted towards phase-2 and early comparative work [1]. The 2025 systematic review uses “GLP-1 receptor agonists” and “GIP/GLP-1 dual agonists” as mechanistic class descriptors for an obesity evidence review [1].

Reading across tiers: preclinical receptor-engagement data describe the mechanism, clinical data describe the registered medicines in their studied populations, and the batch CoA characterises the research material.

Researchers assessing batch-level quality alongside these evidence tiers can consult how to read a CoA to match certificate data to the batch number on the pen, or review the metabolic research pen stack for compound combination context.

Researchers who have worked through the receptor-profile comparison and procurement framework above typically have one of two immediate next steps: understanding the mechanistic detail of a specific compound, or confirming the product specification before placing an order.

For a direct receptor-coverage and evidence contrast between the two catalogue compounds, the retatrutide vs tirzepatide comparison sets the dual against the triple agonist. For the mechanistic step, the Retatrutide triple-agonist profile sets out the compound-specific receptor engagement, published research context and evidence depth for the GLP-1/GIP/glucagon triple-agonist class. That page is the appropriate starting point for researchers who need to characterise Retatrutide’s receptor coverage against their assay design before procurement.

For the product-specification step, the Retatrutide 40 mg research pen carries the verified fill volume, click count and per-click delivery figure for that specific pen format, and the Tirzepatide 40 mg research pen page carries the equivalent specifications for the dual-agonist compound. Confirm those values directly on the product page and cross-reference them against the batch-specific certificate of analysis before finalising any laboratory order.